Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SLN360
Zerlasiran (SLN360) · 2 trials · 6 indications
Clinical trial results (relative to Day 1 pre-dose) was calculated for each participant by estimating the sum of the area under the curve with the linear trapezoidal method for all scheduled assessments from Week 4 to Week 36, inclusive, divided by the total time interval between the Week 4 and Week 36 assessments. Analysis of variance was used to test for differences between each active treatment group and the pooled placebo groups in the primary outcome measure. Time-averaged percent change in lipoprotein(a) to Week 36 was the dependent variable, and treatment group was included as the predictor variable. The least squares means, standard errors, and 2-sided 95% confidence intervals for each treatment group and for the pairwise comparisons between the SLN360 and placebo groups were estimated.
safety and tolerability will be reported separately following single-dose administration.
| Arm | Type | Description |
|---|---|---|
| SLN360 300 mg Q16W | EXPERIMENTAL | SLN360 300 mg administered subcutaneously at Weeks 0, 16 and 32 (Q16W) |
| SLN360 300 mg Q24W | EXPERIMENTAL | SLN360 300 mg administered subcutaneously at Weeks 0 and 24 (Q24W) |
| SLN360 450 mg Q24W | EXPERIMENTAL | SLN360 450 mg administered subcutaneously at Weeks 0 and 24 (Q24W) |
| Placebo Q16W | PLACEBO_COMPARATOR | Placebo administered subcutaneously at Weeks 0, 16 and 32 (Q16W) |
| Placebo Q24W | PLACEBO_COMPARATOR | Placebo administered subcutaneously at Weeks 0 and 24 (Q24W). This group was stratified so that half of participants were dosed to match the SLN360 300 mg Q24W group and half were dosed to match the SLN360 450 mg Q24W group (with respect to injected volume) |
| 30 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 100 mg | EXPERIMENTAL | - |
| 300 mg | EXPERIMENTAL | - |
| 600 mg | EXPERIMENTAL | - |
| 900 mg | EXPERIMENTAL | - |
| 100 mg multi dose | EXPERIMENTAL | - |
| 200 mg multi dose | EXPERIMENTAL | - |
| 300 mg multi dose | EXPERIMENTAL | - |
| 600 mg multi dose | EXPERIMENTAL | - |
| Placebo multi dose | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SLN360 | DRUG | SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA) |
| Placebo | DRUG | Sodium chloride, solution for injection |
Inclusion Criteria: * Lipoprotein(a) at screening equal to or greater than 125 nmol/L * At high risk of ASCVD events * A body mass index at screening in the range of 18.0 to 32.0 kg/m², inclusive Exclusion Criteria: * Renal dysfunction with estimated glomerular filtration rate less than 30 mL/min...
Top 4 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Eloralintide, Lepodisiran |
| Illumina, Inc. | ILMN | 1 | PHASE1 | 18F-mFBG for administration |
Zerlasiran, also known as SLN360, is an investigational RNA therapy being developed for cardiovascular diseases and hyperlipidemias, specifically for people with elevated lipoprotein(a). It is a small interfering RNA (siRNA) therapy developed by Silence Therapeutics and has been studied in Phase 2 and Phase 1 clinical trials.
Zerlasiran is being developed to treat cardiovascular diseases and hyperlipidemias in patients with elevated lipoprotein(a) who are at high risk of atherosclerotic cardiovascular disease events. Its clinical program has enrolled adults with elevated Lp(a), including a Phase 2 study in participants at high risk of atherosclerotic cardiovascular disease events.
Zerlasiran is a small interfering RNA (siRNA) therapy, a class of RNA therapy designed to act through RNA interference. It is being developed for elevated lipoprotein(a) and related cardiovascular conditions. Its clinical trials measured safety, tolerability, pharmacokinetics, and pharmacodynamic response in participants with elevated lipoprotein(a).
Zerlasiran (SLN360) is being developed by Silence Therapeutics Plc, whose American Depositary Shares trade on Nasdaq under the ticker SLN. The company has run both a Phase 1 and a Phase 2 study of the siRNA therapy in participants with elevated lipoprotein(a).
Zerlasiran is in Phase 2 development. Its Phase 2 trial, NCT05537571, has been completed, and an earlier Phase 1 study, NCT04606602, has also been completed. Zerlasiran is an investigational therapy and is not described as FDA approved.
Zerlasiran has been studied in two completed trials. NCT05537571 was a Phase 2, randomized, double-blind, placebo-controlled study of 180 participants with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events, run in Australia, Czechia, Denmark, the Netherlands, Slovakia, South Africa, and the United Kingdom. NCT04606602 was a Phase 1 study of 70 participants.
Yes, Zerlasiran and SLN360 are the same drug. SLN360 is the alternative name for zerlasiran, the siRNA therapy developed by Silence Therapeutics for cardiovascular diseases and hyperlipidemias, including elevated lipoprotein(a). Searches for either name refer to the same investigational asset.